SiRNA therapeutics in the treatment of diseases

Therapeutic Delivery

Volumn 4, Issue 1, 2013, Pages 45-57

  Bakhtiyari, Salar ^a   Haghani, Karimeh ^a   Basati, Gholam ^a   Karimfar, Mohammad Hassan ^a  

^a ILAM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APTAMER; BETA 1,3 GLUCAN; CATIONIC LIPOSOME; CHITOSAN; CYCLODEXTRIN; DENDRIMER; DOUBLE STRANDED RNA; FOMIVIRSEN; LIPOPLEX; LIPOSOME; MAGNETIC NANOPARTICLE; MESSENGER RNA; MICRORNA; NANOPARTICLE; OLIGONUCLEOTIDE; PEGAPTANIB; PEPTIDE DERIVATIVE; PF 4523655; POLYAMIDOAMINE; POLYETHYLENEIMINE; POLYGLACTIN; POLYMER; PROTEIN DERIVATIVE; QUANTUM DOT; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VIROSOME;

ADVANCED CANCER; ALZHEIMER DISEASE; BIOCOMPATIBILITY; BIODEGRADABILITY; CELL THERAPY; CYTOMEGALOVIRUS RETINITIS; DIGESTIVE SYSTEM INFLAMMATION; DISEASES; DNA MODIFICATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; GENE SILENCING; GENE TARGETING; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; JAPANESE ENCEPHALITIS; LUNG EDEMA; METASTASIS; MYOPATHY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARKINSON DISEASE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; RNA SEQUENCE; RNA STABILITY; SEXUALLY TRANSMITTED DISEASE; TREATMENT RESPONSE; VIRUS ENCEPHALITIS; VIRUS INFECTION;

EID: 84871600580     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.136     Document Type: Review

References (128)

1. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell. 2(4), 279-289 (1990).
2. Tijsterman M, Ketting RF, Plasterk RHA. The genetics of RNA silencing. Annu. Rev. Genet. 36(1), 489-519 (2002).
3. Romano N, Macino G. Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences. Mol. Microbiol. 6(22), 3343-3353 (1992).
4. Fire A, Xu SQ, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669), 806-811(1998).
5. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836), 494-498 (2001).
6. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101(1), 25-33 (2000).
7. De Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug. Discov. 6(6), 443-453 (2007).
8. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20(23), 6877-6888 (2001).
9. Perrimon N, Ni JQ, Perkins L. In vivo RNAi: today and tomorrow. Cold Spring Harb Perspect Biol. 2(8), a003640 (2010).
10. Attila AA. RNAi: a potential new class of therapeutic for human genetic disease. Hum. Genet. 130(5), 583-605 (2011).
11. Paul CP, Good PD, Winer I, Engelke DR. Effective expression of small interfering RNA in human cells. Nat. Biotechnol. 20(5), 505-508 (2002).
12. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. RNA 10(5), 766-771 (2004).
13. Shim MS, Wong S, Kwon YJ. siRNA as a conventional drug in the clinic? Challenges and current technologies. Drug. Discov. Today. Tech. 9(2), e167-e173 (2012).
14. Pei Y, Tuschl T. On the art of identifying effective and specific siRNAs. Nat. Methods 3(9), 670-676 (2006).
15. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat. Biotechnol. 22(3), 326-330 (2004).
16. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115(2), 199-208 (2003).
17. Jackson AL, Bartz SR, Schelter J et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21(6), 635-637 (2003).
18. Lin X, Ruan X, Anderson MG et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res. 33(14), 4527-4535 (2005).
19. Qiu S, Adema CM, Lane T. A computational study of off-target effects of RNA interference. Nucleic Acids Res. 33(6), 1834-1847 (2005).
20. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat. Biotechnol. 27, 549-555 (2009).
21. Jackson AL, Burchard J, Leake D et al. Position-specific chemical modification of siRNAs reduces 'off-target' transcript silencing. RNA 12(7), 1197-1205 (2006).
22. Tiemann K, Höhn B, Ehsani A, Forman SJ, Rossi JJ, Sætrom P. Dual-targeting siRNAs. RNA 16(6), 1275-1284 (2010).
23. Schlee M, Hornung V, Hartmann G. siRNA and isRNA: two edges of one sword. Mol. Ther. 14(4), 463-470 (2006).
24. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23(4), 457-462 (2005).
25. Hornung V, Guenthner-Biller M, Bourquin C et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11(3), 263-270 (2005).
26. Kim DH, Longo M, Han Y, Lundberg P, Cantin E, Rossi JJ. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 22(3), 321-325 (2004).
27. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 19(2), 89-102 (2009).
28. Judge AD, Bola G, Lee ACH, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 13(3), 494-505 (2006).
29. Pebernard S, Iggo RD. Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 72(2-3), 103-111 (2004).
30. Ma Z, Li J, He F, Wilson A, Pitt B, Li S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun. 330(3), 755-759 (2005).
31. Higuchi Y, Kawakami S, Hashida M. Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs 24(3), 195-205 (2010).
32. Choung S, Kim YJ, Kim S, Park HO, Choi YC. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 342(3), 919-927 (2006).
33. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8(3), 173-184 (2007).
34. Allerson CR, Sioufi N, Jarres R et al. Fully 2́-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 48(4), 901-904 (2005).
35. Gaglione M, Messere A. Recent progress in chemically modified siRNAs. Mini. Rev. Med. Chem. 10(7), 578-595 (2010).
36. Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum. Gene. Ther. 19(2), 111-124 (2008).
37. Veedu RN, Wengel J. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem. Biodivers. 7(3), 536-542 (2010).
38. Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 18(4), 305-319 (2008).
39. Raouane M, Desmaële D, Urbinati G, Massaad-Massade L, Couvreur P. Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjugate Chem. 3 (6), 1091-1104 (2012).
40. Shukla S, Sumaria CS, Pradeepkumar PI. Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem. 5(3), 328-349 (2010).
41. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol. 28(11), 570-579 (2010).
42. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2(12), 711-719 (2006).
43. Corey DR. Chemical modification: the key to clinical application of RNA interference? J. Clin. Invest. 117(12), 3615-3622 (2007).
44. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296(5567), 550-553 (2002).
45. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes. Dev. 16(8), 948-958 (2002).
46. Fedorov Y, King A, Anderson E et al. Different delivery methods-different expression profiles. Nat. Methods 2(4), 241 (2005).
47. Rossi JJ. Expression strategies for short hairpin RNA interference triggers. Hum. Gene Ther. 19(4), 313-317 (2008).
48. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 6(9), 1130-1146 (2011).
49. Tolentino MJ, Brucker AJ, Fosnot J et al. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 24(4), 660 (2004).
50. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11(1), 50-55 (2004).
51. Lomas-Neira JL, Chung CS, Wesche DE, Perl M, Ayala A. In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury. J. Leukoc. Biol. 77(6), 846-853 (2005).
52. Matsuyama W, Watanabe M, Shirahama Y et al. Suppression of discoidin domain receptor 1 by RNA interference attenuates lung inflammation. J. Immunol. 176(3), 1928-1936 (2006).
53. Thakker DR, Natt F, Hüsken D et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc. Natl Acad. Sci. USA 101(49), 17270-17275 (2004).
54. Thakker D, Natt F, Hüsken D et al. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol. Psychiatry 10(8), 782-789 (2005).
55. Dorn G, Patel S, Wotherspoon G et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 32(5), e49 (2004).
56. Luo MC, Zhang DQ, Ma SW et al. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol. Pain. 1(1), 29 (2005).
57. Tan P, Yang L, Shih H, Lan K, Cheng JT. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther. 12(1), 59-66 (2004).
58. Bhavsar D, Subramanian K, Sethuraman S, Krishnan UM. Translational siRNA therapeutics using liposomal carriers: prospects and challenges. Curr. Gene Ther. 12(4), 315-332 (2012).
59. Schlegel A, Largeau C, Bigey P et al. Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomes. J. Control. Release 152(3), 393-401 (2011).
60. Reich SJ, Fosnot J, Kuroki A et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9(5), 210-216 (2003).
61. Kumar P, Lee SK, Shankar P, Manjunath N. A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS. Med. 3(4), e96 (2006).
62. Palliser D, Chowdhury D, Wang QY et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439(7072), 89-94 (2005).
63. Khoury M, Louis-Plence P, Escriou V et al. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor a in experimental arthritis. Arthritis. Rheum. 54(6), 1867-1877 (2006).
64. Harris TJ, Green JJ, Fung PW, Langer R, Anderson DG, Bhatia SN. Tissue-specific gene delivery via nanoparticle coating. Biomaterials 31(5), 998-1006 (2010).
65. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat. Rev. Drug. Discov. 4(7), 581-593 (2005).
66. Mokhtarieh AA, Cheong S, Kim S, Chung BH, Lee MK. Asymmetric liposome particles with highly efficient encapsulation of siRNA and without nonspecific cell penetration suitable for target-specific delivery. Biochim. Biophys. Acta. 1818(7), 1633-1641 (2012).
67. Morrissey DV, Lockridge JA, Shaw L et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23(8), 1002-1007 (2005).
68. Geisbert TW, Lee AC, Robbins M et al. Post exposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375(9729), 1896-1905 (2010).
69. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12(5), 461-466 (2004).
70. Schaffert D, Troiber C, Salcher EE et al. Solid-phase synthesis of sequence-defined T-, i-, and U-shape polymers for pDNA and siRNA aelivery acids. Angew. Chem. Int. Ed. Engl. 50(38), 8986-8969 (2011).
71. Rudzinski WE, Aminabhavi TM. Chitosan as a carrier for targeted delivery of small interfering RNA. Int. J. Pharm. 399(1-2), 1-11 (2010).
72. Howard KA, Rahbek UL, Liu X et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14(4), 476-484 (2006).
73. Pillé JY, Li H, Blot E et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene. Ther. 17(10), 1019-1026 (2006).
74. Bellocq NC, Pun SH, Jensen GS, Davis ME. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug. Chem. 14(6), 1122-1132 (2003).
75. Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 33(2), 583-591 (2012).
76. Mallipeddi R, Rohan LC. Progress in antiretroviral drug delivery using nanotechnology. Int. J. Nanomedicine. 5, 533-547 (2010).
77. Khan A, Benboubetra M, Sayyed PZ et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J. Drug. Target 12(6), 393e404 (2004).
78. Baigude H, Rana TM. Delivery of therapeutic RNAi by nanovehicles. ChemBioChem 10(15), 2449-2454 (2009).
79. Zatsepin T, Turner J, Oretskaya T, Gait M. Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents. Curr. Pharm. Des. 11(28), 3639-3654 (2005).
80. Kim WJ, Christensen LV, Jo S et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol. Ther. 14(3), 343-350 (2006).
81. Kumar P, Ban HS, Kim SS et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134(4), 577-586 (2008).
82. Eguchi A, Meade BR, Chang YC et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat. Biotechnol. 27(6), 567-571 (2009).
83. Pirollo KF, Rait A, Zhou Q et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 67(7), 2938-2943 (2007).
84. Tan WB, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 28(8), 1565-1571 (2007).
85. Xia CF, Boado RJ, Pardridge WM. Antibody-mediated targeting of siRNA via the human Insulin receptor using avidin-biotin technology. Mol. Pharm. 6(3), 747-751 (2009).
86. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319(5863), 627-630 (2008).
87. Guo P, Coban O, Snead NM et al. Engineering RNA for targeted siRNA delivery and medical application. Adv. Drug. Deliv. Rev. 62(6), 650-666 (2010).
88. Dassie JP, Liu XY, Thomas GS et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 27(9), 839-849 (2009).
89. Yoshizawa T, Hattori Y, Hakoshima M, Koga K, Maitani Y. Folate-linked lipid based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur. J. Pharm. Biopharm. 70(3), 718-725 (2008).
90. Kawakami S, Yamashita F, Nishida K, Nakamura J, Hashida M. Glycosylated cationic liposomes for cell-selective gene delivery. Crit. Rev. Ther. Drug. Carrier. Syst. 19(2), 171-190 (2002).
91. Yezhelyev MV, Qi L, O'Regan RM, Nie S, Gao X. Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J. Am. Chem. Soc. 130(28), 9006-9012 (2008).
92. Mahmoudi M, Hosseinkhani H, Hosseinkhani M et al. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chem. Rev. 111(2), 253-280 (2011).
93. Gavrilov K, Saltzman WM. Therapeutic siRNA: Principles, challenges, and strategies. Yale. J. Biol. Med. 85(2), 187-200 (2012).
94. Namiki Y, Namiki T, Yoshida H et al. A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery. Nat. Nanotechnol. 4(9), 598-606 (2009).
95. Agrawal A, Min DH, Singh N et al. Functional delivery of siRNA in mice using dendriworms. ACS Nano. 3(9), 2495-2504 (2009).
96. Kesharwani P, Tekade RK, Gajbhiye V, Jain K, Jain NK. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine 7(3), 295-304 (2011).
97. Taratula O, Garbuzenko O, Savla R, Wang YA, He H, Minko T. Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Curr. Drug. Deliv. 8(1), 59-69 (2011).
98. Patil ML, Zhang M, Minko T. Multifunctional triblock nanocarrier (PAMAMPEG-PLL) for the efficient intracellular siRNA delivery and gene silencing. ACS. Nano. 5(3), 1877-1887 (2011).
99. Dutta T, Burgess M, McMillan NA, Parekh HS. Dendrosome-based delivery of siRNA against E6 and E7 oncogenes in cervical cancer. Nanomedicine 6(3), 463-470 (2010).
100. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 33(29), 7138-7150 (2012).
101. Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 16(15), 942-946 (2008).
102. Davis ME, Zuckerman JE, Choi CH et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291), 1067-1070 (2010).
103. Taratula O, Garbuzenko OB, Kirkpatrick P et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J. Control. Release 140(3), 284-293 (2009).
104. Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J. Cell. Sci. 123(Pt 8), 1183-1189 (2010).
105. Shao K, Hou Q, Go ML et al. Sulfatidetenascin interaction mediates binding to the extracellular matrix and endocytic uptake of liposomes in glioma cells. Cell. Mol. Life. Sci. 64(4), 506-515 (2007).
106. Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects. EMBO. Mol. Med. 1(3), 142-151 (2009).
107. Choi B, Hwang Y, Kwon HJ et al. Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model. J. Dermatol. Sci. 52(2), 87-97 (2008).
108. Aouadi M, Tesz GJ, Nicoloro SM et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458(7242), 1180-1184 (2009).
109. Gregory JT, Myriam A, Matthieu P et al. Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem. J. 436(2), 351-362 (2011).
110. Jeong JH, Kim SH, Lee M et al. Non-viral systemic delivery of Fas siRNA suppresses cyclophosphamide-induced diabetes in NOD mice. J. Control. Release 143(1), 88-94 (2010).
111. Taniguchi CM, Ueki K, Kahn CR. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J. Clin. Invest. 115(3), 718-727 (2005).
112. Bakhtiyari S, Meshkani R, Taghikhani M, Larijani B, Adeli K. Protein tyrosine phosphatase-1B (PTP-1B) knockdown improves palmitate-induced insulin resistance in C2C12 skeletal muscle cells. Lipids 45(3), 237-244 (2010).
113. Bakhtiyari S, Meshkani R, Taghikhani M, Larijani B. The effects of PTP-1B knockdown on glucose uptake and triglyceride levels in C2C12 skeletal muscle cells. Iranian J. Diabetes Lipid Disord. 9, 1-8 (2010).
114. Zinker BA, Rondinone CM, Trevillyan JM et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl Acad. Sci. USA 99(17), 11357-11367 (2002).
115. Wilcox DM, Yang R, Morgan SJ et al. Delivery of RNAi reagents in murine models of obesity and diabetes. J. RNAi Gene Silencing. 3(1), 225-236 (2007).
116. Ambros V, Chen X. The regulation of genes and genomes by small RNAs. Development 134(9), 1635-1641 (2007).
117. DeVincenzo J, Lambkin-Williams R, Wilkinson T et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl Acad. Sci. USA 107(19), 8800-8805 (2010).
118. Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 133(4), 467-474 (2004).
119. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351(27), 2805-2816 (2004).
120. Santel A, Aleku M, Roder N et al. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin. Cancer. Res. 16(22), 5469-80 (2010).
121. Santel A, Aleku M, Keil O et al. A novel siRNAlipoplex technology for RNA interference in the mouse vascular endothelium. Gene. Ther. 13(16), 1222-1234 (2006).
122. Greenberger LM, Horak ID, Filpula D et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol. Cancer. Ther. 7(11), 3598-3608 (2008).
123. Maples PB, Kumar P, Yu Y et al. FANG vaccine: autologous tumor cell vaccine genitically modified to express GM-CSF and block production of Furin. BioProcess. J. 8(4), 4-14 (2010).
124. Watts JK, Corey DR. Clinical status of duplex RNA. Bioorg. Med. Chem. Lett. 20(11), 3203-3207 (2010).
125. Judge AD, Robbins M, Tavakoli I et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest. 119(3), 661-673 (2009).
126. Seth S, Matsui Y, Fosnaugh K et al. RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol. Ther. 19(5), 928-935 (2011).
127. Lage H, Krühn A. Bacterial delivery of RNAi effectors: transkingdom RNAi. J. Vis. Exp. 42, 2099 (2010).
128. DiGiusto DL, Krishnan A, Li L et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2(36), 36ra43 (2010).